Highest-materiality recent filing
Ventas ups ATM equity capacity to $3.0B; all 12 directors elected at annual meeting
Amendment No. 3 to ATM Sales Agreement raises aggregate gross sales price to $3.0B, excluding prior sales.
Ventas Q1 Normalized FFO $0.94 (+9% YoY); raises FY investment outlook to $3B
Attributable Net Income $0.11 per share; Normalized FFO $0.94 per share (+9% YoY).
Ventas Q4 Normalized FFO $0.89, up 10% YoY; increases quarterly dividend
Q4 Normalized FFO per share $0.89 vs $0.81; FY 2025 Normalized FFO $3.48 vs $3.19.
Ventas reports Q3 2025 Normalized FFO $0.88 (+10% YoY); raises full-year guidance
Net Income Attributable to Common Stockholders per share $0.14 in Q3 2025.
Ventas Q2 Normalized FFO $0.87 (+9% YoY); SHOP Same-Store NOI +13%; guidance raised
Attributable Net Income per share $0.15; Normalized FFO per share $0.87, +9% YoY.
On May 12, 2026, in connection with his previously disclosed retirement on May 1, 2026, Ventas, Inc. (the “Company”) entered into a separation and release agreement with Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. and President and CEO, Lillibridge Healthcare Services, Inc.
Max materiality 0.80 · Median 0.50 · Most common event earnings